REMS Group Offers Consulting Services
Paramus, NJ
In response to the many pharmaceutical, biotech, device and diagnostic companies seeking assistance with the new Food and Drug Administration (FDA) laws, the REMS Group LLC today announced its formation.
"We meet with our clients to review their product attributes, design a REMS program that will meet the FDA's high standards, and implement the REMS initiatives," said Nicole Stouffer, president of the REMS Group. "Our continual focus on enterprise and sales rep training and vital communications helps to ensure timely, successful product launches and continued marketing efforts."
During the drug application process, the FDA requires a REMS plan to ensure that the benefits of a drug outweigh the risks of the drug. In addition, the FDA may require the submission of a REMS for an already-approved drug if the FDA becomes aware of new safety information.
The FDA has since required REMS of various drugs in the new drug application process as well as in the post-approval environment. Notably, the FDA recently announced the first class-wide REMS requirements for opioid drugs.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
